Chiesi agreed to buy KalVista Pharmaceuticals for about $1.9 billion, adding Ekterly (sebetralstat) to its rare disease portfolio. The acquisition is designed to bolster Chiesi’s presence in hereditary angioedema, where Ekterly is an oral, on-demand therapy approved across major markets including the US, EU, UK, and Japan, and has launched with early sales momentum since its 2025 FDA approval.